Introduction
Humaglobin IV Injection or Infusion 2.5 gm/50 ml (IgG) is a type of immunoglobulin (antibody) derived from human blood plasma. It is used to provide passive immunity to individuals with immune deficiencies, autoimmune disorders, or specific infections. IgG is crucial for protecting against a wide range of bacterial and viral infections by neutralizing pathogens and facilitating their removal by the immune system.
Uses
Humaglobin IV Injection or Infusion 2.5 gm/50 ml is used in various clinical settings, including:
- Treatment of primary and secondary immune deficiencies, such as common variable immunodeficiency (CVID) and chronic lymphocytic leukemia
- Prevention and treatment of infections in patients undergoing immunosuppressive therapy or bone marrow transplantation
- Management of autoimmune diseases, such as autoimmune thrombocytopenic purpura (ITP) and Guillain-Barré syndrome
- Post-exposure prophylaxis for certain infections, such as hepatitis B or rabies
- Treatment of specific infections in patients with hypogammaglobulinemia
| Brand Name | Humaglobin |
|---|---|
| Type | IV Injection or Infusion |
| Weight | 2.5 gm/50 ml |
| Generic | Human immunoglobulin-G |
| Manufacturer | City Overseas Ltd. |
| Available in | English বাংলা |
Mechanism of Action
Humaglobin IV Injection or Infusion 2.5 gm/50 ml provides passive immunity by supplying antibodies that bind to and neutralize pathogens. These antibodies enhance the immune response through several mechanisms:
- Neutralization of toxins and pathogens
- Opsonization, which promotes phagocytosis of pathogens by immune cells
- Activation of the complement system, leading to the destruction of pathogens
How Long Does It Take to Work?
The onset of therapeutic effects of human immunoglobulin-G can vary depending on the condition being treated. For passive immunity and immediate protection, effects may be observed within days. For chronic conditions or immune deficiencies, it may take several weeks of regular administration to achieve optimal therapeutic effects.
Absorption
Humaglobin IV Injection or Infusion 2.5 gm/50 ml is administered intravenously or subcutaneously. When administered intravenously, it is directly introduced into the bloodstream and rapidly distributed throughout the body. Subcutaneous administration allows for slower absorption but provides sustained levels of immunoglobulin-G over time.
Route of Elimination
Humaglobin IV Injection or Infusion 2.5 gm/50 ml is primarily eliminated through catabolism in the liver and spleen. The antibodies are broken down by proteolytic enzymes into smaller components that are eventually excreted by the body.
Dosage
Neonates and infants: 5 ml (250 mg)/kg body weight daily on 3 consecutive days. Further infusion may be required depending on the clinical course.Children and adults:
- For combined therapy with antibiotics in severe bacterial or viral infections and A-/Hypogammaglobulinemia: The usual dosage for adults and children is 2500-5000 mg and 50-150 mg/kg respectively (as a single dose) by intravenous drip infusion or direct intravenous infusion. In case of intravenous injection, it should be injected very slowly.
- For Idiopathic Thrombocytopenic Purpura: The usual dose is 200-400 mg/kg daily given for 5 consecutive days. The additional doses are discontinued if an adequate response does not occur.
For Kawasaki Syndrome: The usual dosage is 400 mg/kg daily given for 5 consecutive days (approximately) or 2000 mg daily by intravenous drip infusion. It is recommended that the administration start within 7 days from the onset of Kawasaki Syndrome.
The dosage of human immunoglobulin-G varies depending on the specific condition and patient characteristics. General guidelines include:
- For primary immunodeficiencies: 400 to 800 mg/kg of body weight every 3 to 4 weeks
- For autoimmune diseases: Dosages may range from 1 to 2 g/kg administered as a single infusion or divided doses
- For post-exposure prophylaxis: Dosage depends on the specific infection and exposure risk
Dosage adjustments may be required based on the patient’s clinical response and tolerability.
Administration
Humaglobin IV Injection or Infusion 2.5 gm/50 ml can be administered:
- Intravenously (IV) over several hours using a slow infusion rate to reduce the risk of adverse reactions
- Subcutaneously (SC) as a series of injections or continuous infusion using a pump, depending on the product and treatment plan
Proper technique and aseptic conditions are crucial for both IV and SC administration to ensure safety and efficacy.
Side Effects
Common side effects of human immunoglobulin-G include:
- Headache
- Fever
- Nausea
- Fatigue
- Local reactions at the injection site (e.g., redness, swelling)
Serious side effects may include:
- Allergic reactions or anaphylaxis
- Transfusion-related acute lung injury (TRALI)
- Hemolytic reactions
Toxicity
While human immunoglobulin-G is generally well-tolerated, excessive doses or rapid infusions can lead to toxicity, including renal impairment or hemolysis. Monitoring for signs of adverse reactions and adjusting the infusion rate can help mitigate these risks.
Precautions
Precautions include:
- Monitoring for allergic reactions, especially during the first infusion
- Regular assessment of renal function, particularly in patients with pre-existing kidney conditions
- Adjusting the dosage in patients with a history of thromboembolic events or at high risk for such events
Interaction
Drug Interactions
Humaglobin IV Injection or Infusion 2.5 gm/50 ml may interact with other medications, including:
- Live attenuated vaccines (e.g., measles, mumps, rubella) - may be less effective when administered shortly after receiving immunoglobulin-G
- Medications that affect renal function or increase the risk of thromboembolic events
Food Interactions
Food interactions are not typically a concern with human immunoglobulin-G, as it is administered parenterally.
Disease Interaction
Use with caution in patients with:
- Renal impairment
- Cardiovascular conditions (due to the risk of thromboembolic events)
- History of allergic reactions
Pregnancy Use
Humaglobin IV Injection or Infusion 2.5 gm/50 ml is generally considered safe during pregnancy when used as prescribed. It may be used for specific indications, such as passive immunity or treatment of certain infections. Consult a healthcare provider to evaluate the benefits and risks in the context of pregnancy.
Lactation Use
Humaglobin IV Injection or Infusion 2.5 gm/50 ml is not known to pose a risk to breastfeeding infants. It is generally considered safe to use during lactation, but it is advisable to consult a healthcare provider for personalized guidance.
Acute Overdose
Acute overdose is rare but can lead to severe reactions such as renal impairment or cardiovascular issues. In case of overdose, treatment is supportive and symptomatic, including hydration and monitoring for adverse effects.
Contraindication
Humaglobin IV Injection or Infusion 2.5 gm/50 ml is contraindicated in individuals with:
- Severe hypersensitivity to immunoglobulin preparations
- Selective IgA deficiency with known anti-IgA antibodies (due to risk of severe allergic reactions)
Use Direction
Follow the prescribed dosage and administration instructions carefully. Ensure that proper infusion techniques are used, and monitor for any adverse reactions. Adhere to scheduled follow-ups and assessments to evaluate the effectiveness and adjust treatment as needed.
Storage Conditions
Humaglobin IV Injection or Infusion 2.5 gm/50 ml should be stored according to the manufacturer's instructions, typically in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the medication in its original container, protected from light, and out of reach of children.
Volume of Distribution
The volume of distribution of human immunoglobulin-G is approximately 5 to 7 liters, reflecting its distribution in the extracellular fluid and its ability to diffuse into various body tissues.
Half-Life
The half-life of human immunoglobulin-G is approximately 21 to 30 days. This prolonged half-life allows for less frequent dosing and sustained therapeutic effects over time.
Clearance
Humaglobin IV Injection or Infusion 2.5 gm/50 ml is primarily cleared through the reticuloendothelial system, with its rate of clearance influenced by factors such as renal function and patient-specific characteristics. The clearance rate can vary among individuals based on their health status and other factors.
See in details version Humaglobin IV Injection or Infusion 2.5 gm/50 ml also Humaglobin IV Injection or Infusion 2.5 gm/50 ml in bangla
